Plasma assay of gelatinase B:Tissue inhibitor of metalloproteinase complexes in cancer

✍ Scribed by Stanley Zucker; Rita M. Lysik; Betty I. Dimassimo; Hosein M. Zarrabi; Ute M. Moll; Roger Crimson; Simon P. Tickle; Andrew J. Docherty

• Book ID: 102673917
• Publisher: John Wiley and Sons
• Year: 1995
• Tongue: English
• Weight: 867 KB
• Volume: 76
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19950815)76:4<700::aid-cncr2820760426>3.0.co;2-5

✦ Synopsis

Background. Matrix metalloproteinases (MMPs), especially gelatinase A and gelatinase B (GLB), are believed to be important components of the metastatic process. Tissue Inhibitors of Metalloproteinases (TIMPs) form complexes with MMPs and inhibit cancer dissemination. After local secretion, MMPs and their complexes with TIMPs leach into the blood stream where their concentration can be measured, thereby serving as surrogate markers of disease. Elevated plasma gelatinase B levels have been detected in gastrointestinal cancer and breast cancer. The goal of this study was to determine whether plasma GLB:TIMP complexes also are increased in cancer and whether these tests have potential use as prognostic tumor markers.

Methods. An enzyme-linked immunosorbent assay (ELISA) was developed to measure the plasma concentration of GLB:TIMP complexes in patients with cancer. Correlation between ELISA results and clinical outcome was sought.

Results. Plasma GLB:TIMP complexes were significantly increased in patients with gastrointestinal cancer